You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
The Phosphorylation State of Ser-129 in Human α-Synuclein Determines Neurodegeneration in a Rat Model of Parkinson Disease
Oleg S. Gorbatyuk, Shoudong Li, Layla F. Sullivan, Weijun Chen, Galina Kondrikova, Fredric P. Manfredsson, Ronald J. Mandel and Nicholas Muzyczka
Proceedings of the National Academy of Sciences of the United States of America
Vol. 105, No. 2 (Jan. 15, 2008), pp. 763-768
Published by: National Academy of Sciences
Stable URL: http://www.jstor.org/stable/25451164
Page Count: 6
You can always find the topics here!Topics: Neurons, Phosphorylation, Antibodies, Parkinson disease, Humans, Lewy bodies, Toxicity, Neuroscience, Cell aggregates, Animal models
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
Studies have shown that α-synuclein (α-syn) deposited in Lewy bodies in brain tissue from patients with Parkinson disease (PD) is extensively phosphorylated at Ser-129. We used recombinant Adeno-associated virus (rAAV) to overexpress human wild-type (wt) α-syn and two human α-syn mutants with site-directed replacement of Ser-129 to alanine (S129A) or to aspartate (S129D) in the nigrostriatal tract of the rat to investigate the effect of Ser-129 phosphorylation state on dopaminergic neuron pathology. Rats were injected with rAAV2/5 vectors in the substantia nigra pars compacta (SNc) on one side of the brain; the other side remained as a nontransduced control. The level of human wt or mutant α-syn expressed on the injected side was about four times the endogenous rat α-syn. There was a significant reduction of dopaminergic neurons in the SNc and dopamine (DA) and tyrosine hydroxylase (TH) levels in the striatum of all S129A-treated rats as early as 4 wk postinjection. Nigral DA pathology occurred more slowly in the wt-injected animals, but by 26 wk the wt α-syn group lost nigral TH neurons equivalent to the mutated S129A group at 8 wk. In stark contrast, we did not observe any pathological changes in S129D-treated animals. Therefore, the nonphosphorylated form of S129 exacerbates α-syn-induced nigral pathology, whereas Ser-129 phosphorylation eliminates α-syn-induced nigrostriatal degeneration. This suggests possible new therapeutic targets for Parkinson Disease.
Proceedings of the National Academy of Sciences of the United States of America © 2008 National Academy of Sciences